Lymphadenopathy-associated virus antibodies and T cells in hemophiliacs treated with cryoprecipitate or concentrate.
Evidence for exposure to lymphadenopathy-associated virus (LAV) was investigated in 48 patients with hemophilia, 15 of whom had been treated exclusively with single-donor cryoprecipitate. The prevalence of antibodies to LAV in all patients was 53% in 1983 and 63% in 1984, while in patients treated only with cryoprecipitate, the prevalence was 31% in 1983 and 40% in 1984. Patients treated with any concentrate had a seroprevalence of 65% in 1983 and 77% in 1984. Seropositive patients were more likely to have a significant reduction in the ratio of helper to suppressor T cells, absolute numbers of helper T cells, and T cell function in vitro. Seven of 18 patients who were seronegative in 1983 had seroconverted by 1984. The relative risk of seroconversion for patients using any concentrate since 1981 compared with those using cryoprecipitate only was 3.9 (P = .04). Nevertheless, the rate of conversion in the latter group was 18% per year.
Gjerset
G F
GF
McGrady
G
G
Counts
R B
RB
Martin
P J
PJ
Jason
J
J
Kennedy
S
S
Evatt
B
B
Hansen
J A
JA
D000163:Acquired Immunodeficiency Syndrome / Q000209:etiology; D000293:Adolescent; D000328:Adult; D000914:Antibodies, Viral / Q000032:analysis*; D017977:Deltaretrovirus / Q000276:immunology*; D005169:Factor VIII / Q000009:adverse effects*; D005340:Fibrinogen / Q000009:adverse effects*; D006467:Hemophilia A / Q000150:complications / Q000276:immunology* / Q000628:therapy; D002836:Hemophilia B / Q000276:immunology* / Q000628:therapy; D006801:Humans; D008213:Lymphocyte Activation; D008875:Middle Aged; D013601:T-Lymphocytes / Q000145:classification* / Q000276:immunology
D000914:Antibodies, Viral; C026912:cryoprecipitate coagulum; D005169:Factor VIII; D005340:Fibrinogen